Clinical Scorecard: Addressing the Accessibility Challenges of PSMA PET/CT in Prostate Cancer: Insights, Obstacles, and Implementation Priorities

At a Glance

Key Highlights

• PSMA PET/CT shows higher diagnostic accuracy than CT and bone scintigraphy (92% vs. 65%).
• It can identify disease at PSA levels below conventional imaging detection thresholds.
• Access to PSMA PET/CT is influenced by geography, institution, and reimbursement policies.
• Guidelines recommend PSMA PET/CT for staging and recurrence assessment in specific patient populations.
• Implementation challenges exist despite demonstrated diagnostic value.

Guideline-Based Recommendations

Diagnosis

• PSMA PET/CT is advised for enhancing staging accuracy in unfavourable intermediate-risk disease.
• It is recommended for screening metastases in high-risk or locally advanced disease.

Management

• Following radical prostatectomy, PSMA PET/CT is recommended for PSA recurrence with PSA > 0.2 ng/mL.
• After radiotherapy, it is recommended for patients eligible for curative salvage treatment.

Monitoring & Follow-up

• Timely access to PSMA PET/CT is crucial for informing treatment decisions.

Risks

• Delayed access may lead to less precise localization and treatment planning.

Patient & Prescribing Data

Patients with high-risk localized prostate cancer and those experiencing biochemical recurrence.

PSMA PET/CT may alter treatment intent but direct evidence for improved oncological outcomes is limited.

Clinical Best Practices

• Ensure equitable access to PSMA PET/CT across different healthcare settings.
• Develop access policies in parallel with evidence on how PET findings should modify treatment.

Related Resources & Content

• 2026 EAU Prostate Cancer Guidelines
• EANM/SNMMI Procedure Guideline